Onychomycosis Clinical Trial
Official title:
A Retrospective Evaluation of the Effect of the Erchonia LUNULA™ on the Increase of Clear Nail in Patients With Toenail Onychomycosis
The purpose of this study is to determine whether low level laser therapy (LLLT) using the Erchonia LUNULA device is effective in increasing clear nail in toenails with onychomycosis.
Nail onychomycosis, or fungus infection, is typically caused by a fungus called
dermatophytes, but may also be caused by yeasts and molds. These microscopic organisms
invade the skin through tiny invisible cuts or through a small separation between the nail
and the nail bed. Under conditions of warmth and moisture, the fungi grow and spread. The
infection begins as a white or yellow spot under the tip of the nail, and as it spreads
deeper into the nail, causes unsightly and potentially painful nail discoloration,
thickening and the development of crumbling edges. Onychomycosis occurs more commonly in
toenails than in fingernails because toenails are often confined in a dark, warm, moist
environment inside shoes where fungi can thrive. Toenail fungus affects approximately 23
million people in the US - about 10% of all adults.
Potential complications of onychomycosis include pain in the nails, permanent damage to the
nails, development of other serious infections that can spread beyond the feet for
individuals with a suppressed immune system due to medication, diabetes or other conditions,
such as leukemia and AIDS.
Nail fungus can be difficult to treat, and repeated infections are common. Currently
available treatments for onychomycosis include oral antifungal medications, antifungal
lacquer, and topical medications, surgical nail removal and photodynamic therapy.
There is no perfect cure for toenail fungus. Even the most effective oral medications are
successful only about half of the time, and topical medications are successful less than 10%
of the time. Recently, research has found laser therapy to show promise as a novel
alternative treatment for toenail onychomycosis. Unlike medication-driven treatments for
toenail fungus which can have many side effects including serious ones such as liver
toxicity, laser therapy presents minimal to no risk of side effects. Laser therapy is
applied to toenail onychomycosis by shining a laser light through the toenail into the
tissue below. The laser light vaporizes the fungus while leaving the skin and surrounding
healthy tissue unharmed.
Low level laser therapy operates under the principle of photochemistry with a photoacceptor
molecule absorbing the emitted photons and inducing a biological cascade. Like our
eukaryotic cell, fungi contain the highly complex organelle the mitochondria, which is
responsible for the manufacturing of the energy molecule adenosine triphosphate (ATP).
Within the inner mitochondrial membrane is cytochrome c oxidase, an identified photoacceptor
molecule. It is believed that laser therapy could perhaps provide a means to photo-destroy
the fungi responsible for onychomycosis (OM) by inducing the release of highly reactive
superoxides. Moreover, laser therapy has been shown to promote superoxide dismutase (SOD), a
process responsible for the destruction of foreign invaders. Extracellular release of low
levels of mediators associated with SOD can increase the expression of chemokines,
cytokines, and endothelial leukocyte adhesion molecules, amplifying the cascade that elicits
the inflammatory response. The physiologic function of hydrogen peroxide, superoxide anion,
and hydroxyl free radical is to destroy phagocytosed microbes. By enhancing the natural
processes of the immune system and impacting the structural integrity of the fungi strain,
it is believed that laser therapy may provide a means for clinicians to effectively treat OM
without the onset of any adverse events.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03098615 -
Study Evaluating the Effect of Jublia on Dermatophytomas
|
Phase 4 | |
Recruiting |
NCT01666002 -
Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
|
N/A | |
Completed |
NCT01180491 -
A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis
|
N/A | |
Terminated |
NCT01208129 -
Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
|
Phase 3 | |
Terminated |
NCT01208168 -
Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
|
Phase 3 | |
Completed |
NCT00385502 -
A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail
|
Phase 2 | |
Completed |
NCT00253305 -
Topical Gel Anti-Fungal Agent for Tinea Unguium
|
Phase 2 | |
Not yet recruiting |
NCT05809297 -
Diode Laser and Photodynamic Therapy Vs. Ciclopirox.
|
Phase 4 | |
Completed |
NCT03405818 -
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
|
Phase 4 | |
Recruiting |
NCT02436291 -
Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis
|
Phase 4 | |
Completed |
NCT01851590 -
Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis
|
Phase 4 | |
Completed |
NCT01452490 -
Diode Laser Treatment of Onychomycosis
|
N/A | |
Withdrawn |
NCT00938925 -
Effectiveness of Podiatry Care on Onychomycosis (EPOCAON)
|
N/A | |
Recruiting |
NCT00808366 -
Efficacy and Safety of RV4104A Ointment in Onychomycosis
|
N/A | |
Completed |
NCT00768768 -
Iontophoretic Application of Terbinafine Gel to the Large Toe Nail
|
Phase 1 | |
Completed |
NCT00781820 -
Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste
|
Phase 3 | |
Completed |
NCT00777868 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis
|
Phase 2 | |
Recruiting |
NCT06074315 -
Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis
|
N/A | |
Completed |
NCT01039883 -
A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule
|
Phase 1 | |
Suspended |
NCT05491603 -
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis
|
Phase 2 |